The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
- S Horwitz
- , O A O'Connor
- , B Pro
- , L Trümper
- , S Iyer
- , R Advani
- , N L Bartlett
- , J H Christensen
- , F Morschhauser
- , E Domingo-Domenech
- , G Rossi
- , W S Kim
- , T Feldman
- , T Menne
- , D Belada
- , Á Illés
- , K Tobinai
- , K Tsukasaki
- , S-P Yeh
- , A Shustov
- Memorial Sloan Kettering Cancer Center
- University of Virginia
- Northwestern University in Chicago
- Institut für Humangenetik der Universitätsmedizin Göttingen
- University of Texas MD Anderson Cancer Center
- Stanford Cancer Center
- Washington University School of Medicine
- Centre Hospitalier Universitaire Régional de Lille
- Hospitalet de Llobregat Barcelona
- Azienda Ospedaliera Spedali Civili di Brescia
- Hackensack Meridian Health School of Medicine
- Freeman Hospital Laboratory
- Charles University Hospital
- The University of Debrecen
- National Cancer Center Hospital
- Saitama Medical University International Medical Center
- China Medical University Hospital
- University of Washington
- Universitatsklinikum Essen
- University of British Columbia
- Calvary Mater Newcastle
- Universita Degli Studi Bologna
- Millennium Pharmaceuticals, Inc
- Seagen Inc.
Research output: Contribution to journal › Article › peer-review